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OBJECTIVE: We aimed to evaluate the role of elevated perioperative alanine aminotransferase (ALT) as 
a surrogate marker of hepatitis activity in determining the risk of recurrence and survival in hepatitis 
B-related hepatocellular carcinoma (HCC) after curative hepatectomy.
METHODS: A retrospective review of the hepatectomy database was performed and 142 patients were
found who had hepatitis B-related HCC from January 2001 to March 2006. Their ALT levels preopera-
tively and 1 month, 3 months, and 6 months postoperatively were recorded. The risk factors for recurrence
and prognostic factors of survival were analysed.
RESULTS: An elevated perioperative ALT level (p=0.021), multiple tumour nodules in the resected specimen
(p < 0.001), and a tumour size greater than 5 cm (p = 0.001) were significant independent risk factors for
tumour recurrence. The latter two factors were also independent prognostic factors for overall survival and
disease-free survival. An elevated ALT level was an independent prognostic factor for disease-free survival
(p = 0.025).
CONCLUSION: An elevated perioperative ALT level, which reflects increased hepatitis activity, is an
independent risk factor for intrahepatic recurrence of hepatitis B-related HCC. It is also associated with 
a poorer disease-free survival rate. [Asian J Surg 2008;31(2):41–9]
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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide. The incidence varies greatly
between different geographic regions. In South-East Asia,
where the prevalence of chronic hepatitis B virus infection
is high, the incidence ranges from 28 to 150 per 100,000
population.1 Hepatectomy has been the mainstay of cura-
tive treatment for HCC, but only 10–30% of patients have
resectable disease at the time of diagnosis.2 The outcome
of hepatectomy, however, is jeopardized by the relatively
high incidence of tumour recurrence. A 3-year recurrence
rate of 70% has been reported.3,4 Recurrent disease (either
intrahepatic or extrahepatic) is the major cause of death
after curative resection.
It is believed that intrahepatic recurrence arises not
only because of inadequate resection or metachronous
multicentric occurrences, but also as a result of occult
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intrahepatic metastatic lesions.2,5 Many clinicopathologi-
cal factors have been implicated as risk factors for recur-
rence, including vascular invasion, intrahepatic metastasis,
histological grading, tumour size, and increased alpha-
fetoprotein (AFP) concentration.4 In recent years, attention
has been drawn to the prognostic role of the underlying
cirrhosis and hepatitis activity. Studies that use different
histological grading systems have shown an association
between chronic hepatitis status and prognosis after
resection of HCC.6–12 However, these histological scoring
systems are not readily available in most centres, because
only descriptive reporting on the underlying hepatitis sta-
tus is used during the assessment of the histology of a
non-tumour liver after resection of HCC. Furthermore,
these histological scoring systems are subject to interob-
server and intraobserver variability,13 which makes their
interpretation in a routine clinical setting difficult.
Alanine aminotransferase (ALT), a liver parenchymal
enzyme, is a well-established reference marker in the man-
agement of chronic hepatitis B. The elevation of ALT
results from the host’s immune response to the hepatitis
B virus and reflects the severity of hepatocyte damage.14
It has been shown that the negative predictive value of
ALT for inactive hepatitis is 70–80%,15 and higher serum
ALT has been associated with more severe necroinflam-
mation, although the normal laboratory cutoff values
were not able to differentiate between active or inactive
chronic hepatitis.16 In a study by Tarao et al,17 persistent
elevation of ALT > 80 IU/L was significantly associated
with recurrence in hepatitis C-related HCC after curative
resection. Whether the same value, which is about 1.5-fold
the upper limit of normal ALT, has the same predictive
value in hepatitis B-related HCC is not known. We hypo-
thesized that the average ALT level in the perioperative
period can serve as a surrogate marker of hepatitis activ-
ity in predicting the risk of intrahepatic recurrence. The
aim of this study was to evaluate the role of elevated peri-
operative ALT levels in determining the risk of recurrence
and survival in hepatitis B-related HCC after curative
hepatectomy.
Patients and methods
We reviewed the hepatectomy database of the Department
of Surgery at the Prince of Wales Hospital, Chinese
University of Hong Kong. From January 2001 to March
2006, 215 patients with HCC underwent liver resection.
One hundred and eighty-four patients with positive hep-
atitis B surface antigen (HBsAg) were identified. Patients
with concurrent positive antihepatitis C antibodies (n = 2),
recurrent HCC (n = 16), resection margin involvement by
tumour (n = 13), or early postoperative death (n = 5) were
excluded. Cases with isolated extrahepatic recurrence dur-
ing follow-up (n = 6) were also excluded. The remaining
142 patients were included in this study.
Follow-up
All patients were followed-up regularly at the Joint
Hepatoma Clinic after surgery. They were monitored by
serum AFP and ultrasound or contrast computed tomog-
raphy (CT) every 3–6 months. When clinically indicated, a
hepatic angiogram and post-lipiodol CT scan or image-
guided liver biopsy were performed to confirm HCC
recurrence. The date of the confirmatory imaging or
biopsy was regarded as the time of recurrence. Survival
time was calculated from the date of surgery.
Definition of study parameters
Because hepatitis activity may fluctuate with time, the
postoperative trend of ALT levels is also important to
tumour recurrence. We therefore recorded the preopera-
tive ALT and the ALT at 1 month, 3 months, and 6 months
postoperatively, and used the average ALT > 80 IU/L as the
elevated perioperative ALT level according to previous
experience.17 For pathological assessment of the fibrosis
stage of a non-tumour liver, the classification of Ishak13
was used. The categories were normal (Ishak score 0),
mild to moderate fibrosis (Ishak score 1–4), and severe
fibrosis and cirrhosis (Ishak score 5–6). The extent of
hepatectomy was classified as major or minor according
to the number of Couinaud segments resected. Major
hepatectomy was defined as a resection of ≥ 3 Couinaud
segments.
Analysis of risk factors for recurrence and survival
Eleven clinicopathological factors were evaluated for their
association with recurrence of HCC: ALT level, AFP level,
perioperative blood transfusion, extent of hepatectomy,
grade of liver fibrosis, number of tumour nodules in the
resected specimen, size and histological grading of the
tumour, resection margin, vascular invasion, and American
Joint Committee on Cancer (AJCC) staging. In addition
to these factors, the American Society of Anaesthesiologists
(ASA) class, Child-Pugh class, previous tumour rupture,
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and postoperative complications were included in sur-
vival analysis.
Statistical analysis
Differences in baseline characteristics between groups
were assessed using the χ2 test or Fisher’s exact test for
categorical variables, and the Mann-Whitney U test for
continuous variables. Risk factors of recurrence were eval-
uated by Cox’s proportional hazards model, and variables
with p < 0.05 were included for multivariate analysis.
Survival rates were evaluated using the Kaplan-Meier
method and compared by univariate analysis with the log-
rank test and multivariate analysis using Cox’s proportional
hazards model. All analyses were performed using SPSS
version 11.5 (SPSS Inc., Chicago, IL, USA). Two-tailed 
p values < 0.05 were considered statistically significant.
Results
Clinical characteristics
There were 117 male (82%) and 25 female (18%) patients
in the study. The median age was 53 years (range, 27–74
years). There was no major difference in patient charac-
teristics with respect to different levels of ALT except for
postoperative complications, extent of hepatectomy, and
vascular invasion (Table 1). Although a greater propor-
tion of patients with elevated perioperative ALT under-
went major hepatectomy and developed postoperative
complications compared to the non-elevated ALT group,
these two factors were not significant predictive factors
for recurrence or survival, as subsequent analysis shows
(Tables 2 and 3). The percentage of patients who had vas-
cular invasion was also higher in the elevated ALT group,
but the potential confounding effect was evaluated by mul-
tivariate analysis which showed it was not a significant
prognostic factor (Tables 4 and 5).
The median follow-up period was 30 months (range,
2–75 months). Forty-five (32%) patients had died by the
time of evaluation. The 1-, 3- and 5-year overall survival
rates were 87.2%, 67.1% and 63.7%, respectively, and the 
1-, 3- and 5-year disease-free survival rates were 70.1%,
53.8% and 49.5%, respectively.
HCC recurrence
Sixty-five patients (45.8%) developed intrahepatic recur-
rence. The median time to recurrence was 8 months (range,
1–63 months). There were 26 (40%) solitary recurrences
and 39 (60%) multifocal recurrences. Thirteen patients
(20%) had evidence of extrahepatic recurrence when their
intrahepatic recurrence was diagnosed.
Twenty out of 30 (66.7%) patients with elevated peri-
operative ALT and 45 out of 112 (40.2%) patients without
ALT elevation had HCC recurrence. An elevated ALT level
was a significant independent risk factor for recurrence,
carrying a hazard ratio of 1.9 (95% confidence interval
[CI], 1.10–3.19) (Table 4). Multiple tumour nodules in the
resected specimen (hazard ratio, 3.3; 95% CI, 1.93–5.52)
and tumour size >5 cm (hazard ratio, 2.3; 95% CI, 1.38–3.76)
were the other significant independent risk factors for
recurrence.
Survival
At the time of the last follow-up, 16 out of 30 (53.3%)
patients with elevated ALT levels and 81 out of 112 (72.3%)
patients with low ALT levels had survived. Table 3 sum-
marizes the results of the prognostic factors for overall
and disease-free survival in univariate analysis. An ele-
vated perioperative ALT was a significant prognostic factor
for overall and disease-free survival (Figure) in univariate
analysis. Other prognostic factors for both overall and
disease-free survival in univariate analysis included tumour
size > 5 cm, multiple tumour nodules in the resected spec-
imen, presence of vascular invasion, and AJCC stage III
and IV. In multivariate analysis, only tumour size > 5 cm
and multiple tumour nodules in the resected specimen
were significant independent factors for both overall and
disease-free survival (Table 5). An elevated ALT level was
an independent risk factor for disease-free survival, giving
a hazard ratio of 1.8 (95% CI, 1.07–3.11).
Discussion
The present study showed that an elevated ALT level in
the perioperative period was associated with an increased
risk of intrahepatic recurrence in hepatitis B-related HCC
after curative hepatectomy. It was also a significant prog-
nostic factor for disease-free survival. With these findings,
the prognostic role of perioperative ALT as a surrogate
marker of hepatic inflammation in predicting the risk of
intrahepatic recurrence is highly indicated.
A similar association was also observed in hepatitis 
C-related HCC. Patients with high ALT levels had a signif-
icantly higher recurrence rate and shorter mean duration
to recurrence compared to patients with low ALT levels,
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Table 1. Baseline characteristics according to ALT level*
Patient characteristics
ALT elevation
p
Yes (n = 30) No (n = 112)
Age (yr) 55 (38–72) 53 (27–74) 0.398
Sex 0.105
Male 28 (93.3) 89 (79.5)
Female 2 (6.7) 23 (20.5)
ASA class 0.776
I 11 (36.7) 34 (30.4)
II 18 (60.0) 75 (67.0)
III 1 (3.3) 3 (2.7)
Albumin 41 (32–47) 40 (31–49) 0.344
Bilirubin 10 (6–25) 10 (3–29) 0.125
Platelet count 186 (73–386) 174 (59–338) 0.134
Prothrombin time 11.2 (9.7–14.0) 10.8 (9.5–13.9) 0.075
Alpha-fetoprotein 0.528
> 400 12 (40.0) 38 (33.9)
≤ 400 18 (60.0) 74 (66.1)
Operative time (min) 215 (83–450) 195 (85–490) 0.542
Operative blood loss (mL) 614 (100–3,310) 478 (20–2,238) 0.133
Blood transfusion 0.130
Yes 5 (16.7) 7 (6.3)
No 25 (83.3) 105 (93.8)
Postoperative complication 0.008†
Yes 15 (50.0) 28 (25.0)
No 15 (50.0) 84 (75.0)
Outcome 0.466
Home 25 (83.3) 84 (75.0)
Convalescence 5 (16.7) 28 (25.0)
History of rupture 0.676
Yes 2 (6.7) 6 (5.4)
No 28 (93.3) 106 (94.6)
Hepatectomy 0.038†
Major 17 (56.7) 40 (35.7)
Minor 13 (43.3) 72 (64.3)
Resection margin 0.551
≥ 1 cm 20 (66.7) 68 (60.7)
< 1 cm 10 (33.3) 44 (39.3)
Size of tumour 0.294
> 5 cm 13 (43.3) 37 (33.0)
≤ 5 cm 17 (56.7) 75 (67.0)
(Continued)
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Table 1. (Continued)
Patient characteristics
ALT elevation
p
Yes (n = 30) No (n = 112)
Tumour number 0.381
Solitary 21 (70.0) 87 (77.7)
Multiple 9 (30.0) 25 (22.3)
Tumour differentiation 0.393
Well 3 (10.0) 14 (12.5)
Moderate 24 (80.0) 76 (67.9)
Poor 3 (10.0) 22 (19.6)
Vascular invasion 0.026†
Yes 8 (26.7) 12 (10.7)
No 22 (73.3) 100 (89.3)
Encapsulation 1.000
Yes 18 (60.0) 67 (59.8)
No 12 (40.0) 45 (40.2)
Fibrosis score 0.455
0 2 (6.7) 8 (7.1)
1–4 15 (50) 42 (37.5)
5–6 13 (43.3) 62 (55.4)
AJCC stage 0.142
I & II 22 (73.3) 95 (84.8)
III & IV 8 (26.7) 17 (15.2)
*Data are presented as median (range) or n (%); †statistically significantly different. ALT = alanine aminotransferase; ASA = American Society
of Anaesthesiologists; AJCC = American Joint Committee on Cancer.
Table 2. Univariate analysis for factors associated with recurrence
Variable Hazard ratio 95% confidence interval p
Elevated ALT 2.0 1.18–3.40 0.010*
AFP > 400 2.0 1.23–3.26 0.005*
Blood transfusion 0.9 0.36–2.28 0.845
Minor hepatectomy 0.9 0.60–1.63 0.966
Margin < 1 cm 0.8 0.50–1.39 0.495
Size > 5 cm 2.5 1.55–4.13 < 0.001*
Multiple tumours 3.6 2.19–6.13 < 0.001*
Poorly differentiated tumour 1.4 0.80–2.62 0.222
Vascular invasion 2.8 1.53–5.13 0.001
Fibrosis score†
1–4 1.3 0.39–4.30 0.671
5–6 1.3 0.40–4.20 0.676
AJCC stage III & VI vs. I & II 3.3 1.93–5.80 < 0.001*
*Statistically significantly different; †hazard ratio given is relative to a fibrosis score of 0. ALT = alanine aminotransferase; AFP = alpha-
fetoprotein; AJCC = American Joint Committee on Cancer.
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Table 3. Univariate analysis for prognostic factors of survival
Prognostic factor
Overall survival (mo) Disease-free survival (mo)
n
Mean SE p Mean SE p
ASA class 0.890 0.893
I 45 53.3 4.5 46.0 5.0
II 93 53.3 2.9 41.5 3.3
III 4 53.1 14.6 43.5 16.8
Childs-Pugh class 0.397 0.050
A 140 54.5 2.5 44.0 2.8
B 2 32.6 0.0 8.7 3.7
ALT 0.025* 0.010*
≤ 80 112 56.8 2.7 47.0 3.1
> 80 30 43.6 5.6 30.7 5.3
AFP 0.540 0.006*
≤ 400 92 55.4 3.0 48.9 3.4
> 400 50 50.1 4.2 33.2 4.3
Blood transfusion 0.506 0.833
No 130 54.8 2.6 43.6 2.9
Yes 12 47.4 8.1 39.4 9.4
Postoperative complication 0.940 0.644
No 99 54.0 3.0 43.9 3.3
Yes 43 52.7 4.4 40.9 5.0
History of rupture 0.645 0.169
No 134 54.5 2.5 44.1 2.9
Yes 8 45.8 11.7 29.2 11.7
Hepatectomy 0.484 0.842
Major 57 50.9 3.8 41.3 4.2
Minor 85 55.5 3.2 44.1 3.6
Margin 0.239 0.435
≥ 1 cm 88 50.8 3.1 40.8 3.4
< 1 cm 54 57.6 3.9 46.4 4.5
Tumour size < 0.001* < 0.001*
≤ 5 cm 92 60.4 2.6 50.4 3.2
> 5 cm 50 40.6 4.6 30.0 4.6
Tumour number < 0.001* < 0.001*
Solitary 108 56.9 2.5 49.3 2.9
Multiple 34 37.2 5.9 21.6 5.0
Tumour differentiation 0.065 0.133
Well & moderate 117 56.1 2.7 45.1 3.1
Poor 25 42.6 6.2 34.1 6.3
Vascular invasion < 0.001* < 0.001*
No 122 57.2 2.5 46.6 2.9
Yes 20 33.0 6.7 20.7 5.0
(Continued)
and they were at increased risk of multicentric carcino-
genesis.17–19 Furthermore, increased hepatic inflamma-
tion and worsening fibrosis were significant risk factors
for developing HCC in chronic hepatitis C infection.20 A
relationship between necroinflammation of the liver and
hepatocarcinogenesis is highly suspected. The repeated
cycles of necroinflammation, degeneration, and regenera-
tion increase hepatocyte turnover, which in turn facili-
tates spontaneous mutation and may hinder DNA repair.
The release of reactive oxygen species because of inflam-
mation may also contribute to the loss of control of cell
growth, apoptosis, and senescence. All these types of hepatic
damage may favour HCC recurrence in the background 
of hepatic inflammation.21 Similarly, the inflamed liver
may provide a good environment for occult intrahepatic
metastases to grow in response to the different growth
factors that are available.22,23
Although an elevated perioperative ALT level was an
independent risk factor of disease-free survival, we were
unable to demonstrate its association with overall survival
in multivariate analysis, as in other series.9,10 This might
be because our follow-up period (median, 30 months) was
relatively short compared to that of other series (median,
> 43 months), such that some recurrence-related mortali-
ties had not occurred. Because of the availability of effective
treatment in controlling HCC recurrence,24 the overall
■ ELEVATED ALT LEVEL & HCC RECURRENCE ■
ASIAN JOURNAL OF SURGERY VOL 31 • NO 2 • APRIL 2008 47
Table 3. (Continued)
Prognostic factor
Overall survival (mo) Disease-free survival (mo)
n
Mean SE p Mean SE p
Fibrosis score 0.656 0.901
0 10 29.0 2.9 21.8 3.6
1–4 57 56.8 3.8 44.1 4.3
5–6 73 51.1 3.3 41.6 3.7
AJCC staging < 0.001* < 0.001*
I & II 117 57.2 2.6 48.1 3.0
III & IV 25 37.2 6.7 20.9 5.7
*Statistically significantly different. SE = standard error; ASA = American Society of Anaesthesiologists; ALT = alanine aminotransferase; 
AFP = alpha-fetoprotein; AJCC = American Joint Committee on Cancer.
Table 4. Independent risk factors of recurrence in multivariate analysis
Variable Hazard ratio 95% confidence interval p
Elevated ALT 1.9 1.10–3.19 0.021
Multiple tumours 3.3 1.93–5.52 < 0.001
Size > 5 cm 2.3 1.38–3.76 0.001
ALT = alanine aminotransferase.
Table 5. Independent prognostic factors of survival in multivariate analysis
Survival Prognostic factor Hazard ratio 95% confidence interval p
Overall Multiple tumours 2.5 1.35–4.83 0.004*
Size > 5 cm 2.8 1.56–5.17 0.001*
Elevated ALT 1.8 0.97–3.48 0.063
Disease-free Multiple tumours 3.4 2.04–5.79 <0.001*
Size > 5 cm 2.4 1.43–3.87 0.001*
Elevated ALT 1.8 1.07–3.11 0.025*
*Statistically significantly different. ALT = alanine aminotransferase.
survival for these patients might be longer than our follow-
up period, and recurrence-related mortality would not yet
have occurred for some patients.
In contrast to the findings of other studies,9,10 the
fibrosis stage of a non-tumour liver did not show a signif-
icant association with recurrence and survival in our study.
This was probably caused by the difference in the follow-
up period and the mechanism of recurrence. The study by
Malcolm et al9 included patients who had survived for
more than 5 years, which was much longer than the
median survival of our patients. Their postulated mecha-
nism of recurrence was a development of new metachro-
nous HCC. In our series, most of the recurrences occurred
within the first year, and they were more likely to be intra-
hepatic metastases from the primary tumour, though we
did not have molecular evidence to confirm this.
The limitation of our study was its retrospective design,
and we did not have aspartate aminotransferase and hep-
atitis B virus DNA levels for comparison because these
tests are not routinely available in our hospital. The study
by Sung et al25 demonstrated that using hepatitis B virus
DNA could improve the overall accuracy in predicting
active hepatitis in addition to elevated ALT levels in HBeAg-
negative patients. With the current findings, a prospective
evaluation using the DNA level as a more direct surrogate
marker for hepatitis activity may be possible.
In conclusion, an elevated perioperative ALT level and
possibly increased hepatitis activity are independent risk
factors of intrahepatic recurrence in hepatitis B-related
HCC. An elevated perioperative ALT level is also associated
with poorer disease-free survival. Further prospective studies
to confirm the association between increased viral activ-
ity and elevated hepatitis activity are warranted. Because
most of the risk factors of HCC recurrence and prognostic
factors of survival were tumour related, little could be done
after curative resection. Intervention to reduce the hepa-
titis activity would be a logical approach to reducing the
incidence of recurrence and improving survival. Antiviral
treatment in the perioperative period that aims to nor-
malize the ALT level and reduce the coexisting liver inflam-
mation may be a potentially useful adjuvant therapy for
patients who have significant hepatitis activity.
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